publication venue for
- Continuous treatment with secukinumab 300 mg demonstrates sustained efficacy in clearing skin, and improving patient-reported outcomes in moderate-to-severe plaque-psoriasis: Two-year results from the CLEAR-study 2018
- Secukinumab 300 mg demonstrates highest probability of efficacy than other biologics in psoriasis: indirect comparison 2015
- Secukinumab shows sustained response in subjects with moderate-to-severe plaque psoriasis: a subanalysis of the ERASURE phase 3 study 2015
- Topical fixed-dose adapalene/benzoyl peroxide plus oral doxycycline: An evidence-based alternative to oral Isotretinoin in the treatment of severe nodular acne 2014
- Sun protection behaviour checklist for targeted counselling in skin cancer patients. 63:392-394. 2022
- Corrigendum. 58:160-160. 2017
- Patient experiences and outcomes following facial skin cancer surgery: A qualitative study. 57:e100-e104. 2016
- THE EFFECT OF BACTERIAL COLONIZATION ON VENOUS ULCER HEALING. 33:75-80. 1992